4599

StemRIM Inc.

ステムリム

Industry
Pharmaceutical
Market
Growth
Accounting standards
Japanese GAAP
Consolidation basis
Non-consolidated

Key metrics

Revenue(thousand JPY)

Jul 2021
1,400,000
Jul 2022
22,976
Jul 2023
2,350,000
Jul 2024
-
Jul 2025
-

Operating profit(thousand JPY)

Jul 2021
-593,729
Jul 2022
-1,980,687
Jul 2023
142,391
Jul 2024
-2,076,084
Jul 2025
-1,971,532

Operating profit margin(%)

Jul 2021
-42.41
Jul 2022
-8,620.68
Jul 2023
6.06
Jul 2024
-
Jul 2025
-

Profit before tax(thousand JPY)

Jul 2021
-576,043
Jul 2022
-1,946,224
Jul 2023
170,207
Jul 2024
-2,018,825
Jul 2025
-1,927,784

Profit(thousand JPY)

Jul 2021
-582,448
Jul 2022
-1,948,307
Jul 2023
168,350
Jul 2024
-2,022,166
Jul 2025
-1,929,437

Total assets(thousand JPY)

Jul 2021
10,909,279
Jul 2022
9,597,373
Jul 2023
10,706,482
Jul 2024
9,080,415
Jul 2025
7,518,659

Cash and cash equivalents(thousand JPY)

Jul 2021
10,172,222
Jul 2022
8,880,191
Jul 2023
10,217,764
Jul 2024
8,410,449
Jul 2025
6,994,592

Cash flows from operating activities(thousand JPY)

Jul 2021
-519,649
Jul 2022
-1,404,565
Jul 2023
1,135,315
Jul 2024
-1,881,497
Jul 2025
-1,414,608

Cash flows from investing activities(thousand JPY)

Jul 2021
-92,715
Jul 2022
-330
Jul 2023
-344
Jul 2024
-4,784
Jul 2025
-42,498

Cash flows from financing activities(thousand JPY)

Jul 2021
109,317
Jul 2022
112,859
Jul 2023
202,602
Jul 2024
78,966
Jul 2025
41,250

Return on equity(%)

Jul 2021
-
Jul 2022
-
Jul 2023
1.9
Jul 2024
-
Jul 2025
-

Equity ratio(%)

Jul 2021
94.4
Jul 2022
88.7
Jul 2023
85.9
Jul 2024
83.4
Jul 2025
78

Earnings per share(JPY per share)

Jul 2021
-10.02
Jul 2022
-32.92
Jul 2023
2.8
Jul 2024
-32.98
Jul 2025
-31.16

Net assets per share(JPY per share)

Jul 2021
174.98
Jul 2022
143.32
Jul 2023
151.05
Jul 2024
123.2
Jul 2025
94.33

Dividend per share(-)

Jul 2021
-
Jul 2022
-
Jul 2023
-
Jul 2024
-
Jul 2025
-

Payout ratio(-)

Jul 2021
-
Jul 2022
-
Jul 2023
-
Jul 2024
-
Jul 2025
-

Disclaimer

The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.

The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.